Return On Equity in % of NeuBase Therapeutics, Inc. from Q1 2012 to Q3 2023

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
NeuBase Therapeutics, Inc. quarterly and annual Return On Equity history and change rate from Q1 2012 to Q3 2023.
  • NeuBase Therapeutics, Inc. Return On Equity for the quarter ending 30 Sep 2023 was -104%, a 6.35% decline year-over-year.
  • NeuBase Therapeutics, Inc. annual Return On Equity for 2022 was -97%, a 59.7% decline from 2021.
  • NeuBase Therapeutics, Inc. annual Return On Equity for 2021 was -61%, a 32.5% increase from 2020.
  • NeuBase Therapeutics, Inc. annual Return On Equity for 2020 was -90%, a 94.7% increase from 2019.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Change (%)
Return On Equity, Annual (%)
Return On Equity, YoY Annual Change (%)

NeuBase Therapeutics, Inc. Quarterly Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
Q3 2023 -104% -6% -6.3% 01 Jul 2023 30 Sep 2023
Q2 2023 -116% -38% -48% 01 Apr 2023 30 Jun 2023
Q1 2023 -114% -47% -70% 01 Jan 2023 31 Mar 2023
Q4 2022 -111% -48% -77% 01 Oct 2022 31 Dec 2022
Q3 2022 -97% -36% -60% 01 Jul 2022 30 Sep 2022
Q2 2022 -79% -15% -23% 01 Apr 2022 30 Jun 2022
Q1 2022 -67% -6% -9.8% 01 Jan 2022 31 Mar 2022
Q4 2021 -63% +6% +8.9% 01 Oct 2021 31 Dec 2021
Q3 2021 -61% +29% +33% 01 Jul 2021 30 Sep 2021
Q2 2021 -64% +175% +73% 01 Apr 2021 30 Jun 2021
Q1 2021 -61% +614% +91% 01 Jan 2021 31 Mar 2021
Q4 2020 -69% +794% +92% 01 Oct 2020 31 Dec 2020
Q3 2020 -90% +1,626% +95% 01 Jul 2020 30 Sep 2020
Q2 2020 -239% -801% -142% 01 Apr 2020 30 Jun 2020
Q1 2020 -675% -570% -541% 01 Jan 2020 31 Mar 2020
Q4 2019 -863% -814% -1,643% 01 Oct 2019 31 Dec 2019
Q3 2019 -1,717% -1,704% -13,410% 01 Jul 2019 30 Sep 2019
Q2 2019 562% +625% 01 Apr 2019 30 Jun 2019
Q1 2019 -105% -35% -50% 01 Jan 2019 31 Mar 2019
Q4 2018 -50% +45% +47% 01 Oct 2018 31 Dec 2018
Q3 2018 -13% +87% +87% 28 Aug 2018 30 Sep 2018
Q2 2018 -63% +41% +39% 01 Apr 2018 30 Jun 2018
Q1 2018 -70% +48% +40% 01 Jan 2018 31 Mar 2018
Q4 2017 -94% -2% -2.2% 01 Oct 2017 31 Dec 2017
Q3 2017 -100% -20% -25% 01 Jul 2017 30 Sep 2017
Q2 2017 -104% -40% -64% 01 Apr 2017 30 Jun 2017
Q1 2017 -118% -72% -156% 01 Jan 2017 31 Mar 2017
Q4 2016 -92% -54% -140% 01 Oct 2016 31 Dec 2016
Q3 2016 -80% -42% -110% 01 Jul 2016 30 Sep 2016
Q2 2016 -63% -23% -57% 01 Apr 2016 30 Jun 2016
Q1 2016 -46% -5% -11% 01 Jan 2016 31 Mar 2016
Q4 2015 -38% +19% +33% 01 Oct 2015 31 Dec 2015
Q3 2015 -38% +20% +34% 01 Jul 2015 30 Sep 2015
Q2 2015 -40% +35% +47% 01 Apr 2015 30 Jun 2015
Q1 2015 -41% +105% +72% 01 Jan 2015 31 Mar 2015
Q4 2014 -57% +61% +52% 01 Oct 2014 31 Dec 2014
Q3 2014 -58% +96% +62% 01 Jul 2014 30 Sep 2014
Q2 2014 -75% +52% +41% 01 Apr 2014 30 Jun 2014
Q1 2014 -146% +68% +32% 01 Jan 2014 31 Mar 2014
Q4 2013 -118% +539% +82% 01 Oct 2013 31 Dec 2013
Q3 2013 -154% -531% -141% 01 Jul 2013 30 Sep 2013
Q2 2013 -128% -259% -197% 01 Apr 2013 30 Jun 2013
Q1 2013 -214% -393% -220% 01 Jan 2013 31 Mar 2013
Q4 2012 -657% 01 Oct 2012 31 Dec 2012
Q3 2012 377% 01 Jul 2012 30 Sep 2012
Q2 2012 132% 01 Apr 2012 30 Jun 2012
Q1 2012 178% 01 Jan 2012 31 Mar 2012

NeuBase Therapeutics, Inc. Annual Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
2022 -97% -36% -60% 01 Oct 2021 30 Sep 2022
2021 -61% +29% +33% 01 Oct 2020 30 Sep 2021
2020 -90% +1,626% +95% 01 Oct 2019 30 Sep 2020
2019 -1,717% -1,620% -1,666% 01 Oct 2018 30 Sep 2019
2018 -97% +3% +2.8% 01 Oct 2017 30 Sep 2018
2017 -100% -20% -25% 01 Oct 2016 30 Sep 2017
2016 -80% -42% -110% 01 Oct 2015 30 Sep 2016
2015 -38% +20% +34% 01 Oct 2014 30 Sep 2015
2014 -58% +96% +62% 01 Oct 2013 30 Sep 2014
2013 -154% -531% -141% 01 Oct 2012 30 Sep 2013
2012 377% 01 Oct 2011 30 Sep 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.